| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE39030 | LILLY | Fluoxetine enteric pellets and methods for their preparation and use |
May, 2017
(6 years ago) | |
| US5985322 | LILLY | Method for the treatment of CNS disorders |
May, 2017
(6 years ago) | |
| US5910319 | LILLY | Fluoxetine enteric pellets and methods for their preparation and use |
May, 2017
(6 years ago) | |
|
US5910319 (Pediatric) | LILLY | Fluoxetine enteric pellets and methods for their preparation and use |
Nov, 2017
(6 years ago) | |
|
US5985322 (Pediatric) | LILLY | Method for the treatment of CNS disorders |
Nov, 2017
(6 years ago) | |
Prozac Weekly is owned by Lilly.
Prozac Weekly contains Fluoxetine Hydrochloride.
Prozac Weekly has a total of 5 drug patents out of which 5 drug patents have expired.
Expired drug patents of Prozac Weekly are:
- USRE39030
- US5985322
- US5910319
- US5910319*PED
- US5985322*PED
Prozac Weekly was authorised for market use on 26 February, 2001.
Prozac Weekly is available in capsule, delayed rel pellets;oral dosage forms.
Prozac Weekly can be used as method of treating people suffering from depression, method of treating people suffering from depression without an increase in nausea.
The generics of Prozac Weekly are possible to be released after 29 November, 2017.
Drugs and Companies using FLUOXETINE HYDROCHLORIDE ingredient
Market Authorisation Date: 26 February, 2001
Treatment: Method of treating people suffering from depression without an increase in nausea; Method of treating people suffering from depression
Dosage: CAPSULE, DELAYED REL PELLETS;ORAL
PROZAC WEEKLY family patents
